Clinical Trial Update: Tegaderm and Visual Evoked Potentials

View source ↗

Summary

The Rutgers-sponsored trial investigating Tegaderm in conjunction with visual evoked potentials for pituitary/suprasellar region tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pituitary Tumor

Drugs mentioned

• Tegaderm

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Tumor of Pituitary and Suprasellar Region | Status: TERMINATED